Provider of home care services including personal care, hospice and home health, mainly for Medicaid-eligible seniors.
Provider of home care services including personal care, hospice and home health, mainly for Medicaid-eligible seniors.
Paid mostly by state programs such as Illinois's, which set an hourly rate for personal care, so state budgets and wage rules matter more than competition. Personal care is the base, while hospice and home health, paid by Medicare, are faster-growing parts. It has grown by buying smaller agencies.
Moat: narrow (scale, regulatory licence). State Medicaid contracts and multi-state licensure create barriers for smaller regional home-care providers.
Headquarters: Frisco, Texas · Founded: 1979 · Employees: 50,659
Size Addus HomeCare (ADUS) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.25B, the 1702nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $120.85 on 18 Nov 2026.
Performance Over six months the shares gained 28.9%, against +19.1% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 11.5% over the last twelve months (peer median +4.6%); the operating margin is 11.1% (peer median 7.5%).
Valuation It trades at 16.2× forward earnings against a peer median of 39.5× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.8 points above its cost of capital (8.7% WACC).
Short interest Short interest is 5.3% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.50B | $1.42B | $1.15B | $1.06B | $951M |
| Revenue growth | — | +23% | +9% | +11% | — |
| Gross profit | $469M | $445M | $361M | $329M | $290M |
| EBITDA | $184M | $165M | $129M | $111M | $93.5M |
| Net income | $111M | $95.9M | $73.6M | $62.5M | $46.0M |
| Free cash flow | $144M | $104M | $110M | $103M | $96.8M |
| Capital expenditure | $7.82M | $7.72M | $6.05M | $9.45M | $8.30M |
| Total debt | $67.3M | $171M | $273M | $175M | $178M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Addus HomeCare ADUS | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% |
| Aveanna Healthcare AVAH | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% |
| BrightSpring Health Services BTSG | $13.6B | +17% | +23% | 4% | 28.8× | 24.9% |
| Pennant PNTG | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% |
| Chemed CHE | $7.12B | +24% | +5% | 14% | 20.2× | 3.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ADUS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.4% | -0.3% | 10th highest of 21 |
| 6-month return | +28.9% | +19.1% | 7th highest of 21 |
| Distance from 52-week high | -8.2% | -19.6% | 9th highest of 21 |
| Revenue growth (TTM) | +11.5% | +4.6% | 8th highest of 21 |
| Operating margin | 11.1% | 7.5% | 6th highest of 21 |
| Forward P/E | 16.2× | 39.5× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 4.0% | 8.7% | 5th least demanding of 15 |
| Growth delivered (Del g) | +13.2% | +8.1% | 5th highest of 15 |
| Hurdle (Req g minus delivered) | -9.2 pp | +7.0 pp | 2nd least demanding of 15 |
| ROIC minus cost of capital | +2.8 pp | -1.7 pp | 6th highest of 20 |
| EV / EBITDA | 12.1× | 11.7× | 7th most expensive of 14 |
| Net debt / EBITDA | -0.2× | 2.2× | 3rd least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% | +13.2% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% | +10.2% |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% | +14.6% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 12.4× | -4.4% | +2.0% |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% | +3.9% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 49.6× | 4.2% | +5.7% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| Acadia Healthcare ACHC | United States | $3.49B | +56% | +4% | 10% | 18.6× | n/a | n/a |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.53B | +15% | +17% | 24% | 50.5× | 32.3% | +11.8% |